Odyssey Therapeutics files for proposed IPO

Odyssey Therapeutics has on Friday filed for a proposed Nasdaq IPO.

The company describes itself as: "Odyssey is a clinical-stage biopharmaceutical company led by a team and board of drug hunters seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. We believe our deep understanding of immunobiology, coupled with leading expertise in medicinal and computational chemistry, protein biochemistry, structural biology, genetics, and pharmacology, allows us to identify and drug key signaling nodes that drive disease. We have prioritized targets where we believe the underlying disease biology is understood through genetic, clinical, or translational evidence."

J.P. Morgan, TD Cowen, and Cantor will serve as lead underwriters.

You May Also Be Interested In

• Anthropic plans IPO potentially exceeding SpaceX's $86B record - Bloomberg
• Simmons Bank chief data officer Lisa Hunter to retire
• United Airlines expands Denver pilot training center, phase two planned